Sanofi-Pasteur's quad flu vaccine now at the FDA
This article was originally published in Scrip
The US FDA has accepted for review Sanofi-Pasteur's quadrivalent flu vaccine Fluzone (influenza virus vaccine) and an action date is due in the second quarter of 2013. The company is trailing MedImmune (AstraZeneca) and GlaxoSmithKline to market in this new four-pronged approach to seasonal flu prevention. Currently trivalent 'flu vaccines are the norm (containing two A and one B strain), but there is a move towards quadrivalent product with two B strains to provide more comprehensive protection.